Von Willebrand factor, soluble P-selectin, and target organ damage in hypertension: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)

Hypertension. 2002 Jul;40(1):61-6. doi: 10.1161/01.hyp.0000022061.12297.2e.

Abstract

To investigate the relationship between soluble markers of platelet, endothelial and rheological function, and target organ damage and their response to intensified management in a population of middle-age hypertensive patients at high risk of cardiovascular complications, we studied 382 consecutive patients (308 men; mean age, 63 years, SD 8) along with 60 normotensive controls free of cardiovascular disease. Patients were divided into those with target organ damage (TOD; n=107) and those free of end-organ damage. Plasma levels of soluble P-selectin (sP-sel), a marker of platelet activation, and von Willebrand factor (vWF), an index of endothelial damage/dysfunction (both enzyme-linked immunosorbent assay), and the rheological indices fibrinogen, plasma viscosity, hematocrit, platelet, and white cell count were measured. In 53 patients, variables were further measured after 6 months of intensified cardiovascular risk management. Patients with TOD had significantly higher vWF, 137 (SD 33) versus 125 (SD 33) IU/dL (P=0.002,) and a greater proportion of smokers, 31% versus 16% (P=0.002). There were no statistically significant differences in plasma viscosity, fibrinogen, hematocrit, white blood cell count, platelet count, or sP-sel between the 2 subgroups. In multivariate analysis, vWF was a significant independent predictor for TOD. After 6 months of intensified management in 53 patients who entered the trial, there were significant reductions in systolic blood pressure, total cholesterol, hematocrit, plasma viscosity, sP-sel, and vWF (all P<0.01) but no significant change in fibrinogen. In conclusion, there is a relationship between TOD and endothelial damage/dysfunction in hypertension. Intensified management results in improvements in hemorheology, endothelial and platelet function.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Amlodipine / therapeutic use
  • Antihypertensive Agents / therapeutic use*
  • Atenolol / therapeutic use
  • Bendroflumethiazide / therapeutic use
  • Blood Pressure / drug effects
  • Cross-Sectional Studies
  • Electrocardiography
  • Female
  • Hematocrit
  • Hemorheology / drug effects
  • Humans
  • Hypertension / blood
  • Hypertension / drug therapy*
  • Hypertension / physiopathology
  • Hypertrophy, Left Ventricular / pathology
  • Hypertrophy, Left Ventricular / physiopathology*
  • Male
  • Middle Aged
  • P-Selectin / blood
  • P-Selectin / drug effects*
  • Perindopril / therapeutic use
  • Regression Analysis
  • Single-Blind Method
  • Treatment Outcome
  • von Willebrand Factor / drug effects*
  • von Willebrand Factor / metabolism

Substances

  • Antihypertensive Agents
  • P-Selectin
  • von Willebrand Factor
  • Amlodipine
  • Atenolol
  • Bendroflumethiazide
  • Perindopril